CoChat
Sign Up
Cited by 47Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsClinical Laboratory Practices and Quality Control

Accuracy of plasma Aβ40, Aβ42, and p‐tau181 to detect CSF Alzheimer's pathological changes in cognitively unimpaired subjects using the Lumipulse automated platform

Open access
Martínez-Dubarbie, Francisco, Guerra-Ruiz, Armando, López-García, Sara, Lage, Carmen, Fernández-Matarrubia, Marta, Infante, Jon, Pozueta-Cantudo, Ana, García-Martínez, María +7 more·2023·Alzheimer's Research & Therapy
DOI 10.1186/s13195-023-01319-1PMC PMC10544460
Open this paper in CoChat — free accountOpen PDF

Abstract

Background: The arrival of new disease-modifying treatments for Alzheimer’s disease (AD) requires the identification of subjects at risk in a simple, inexpensive, and non-invasive way. With tools allowing an adequate screening, it would be possible to optimize the use of these treatments. Plasma markers of AD are very promising, but it is necessary to prove that alterations in their levels are related to alterations in gold standard markers such as cerebrospinal fluid or PET imaging. With this research, we want to evaluate the performance of plasma Aβ40, Aβ42, and p-tau181 to detect the pathological changes in CSF using the automated Lumipulse platform. Methods: Both plasma and CSF Aβ40, Aβ42, and p-tau181 have been evaluated in a group of 208 cognitively unimpaired subjects with a 30.3% of ApoE 4 carriers. We have correlated plasma and CSF values of each biomarker. Then, we have also assessed the differences in plasma marker values according to amyloid status (A − / +), AD status (considering AD + subjects to those A + plus Tau +), and ATN group defined by CSF. Finally, ROC curves have been performed, and the area under the curve has been measured using amyloid status and AD status as an outcome and different combinations of plasma markers as predictors. Results: Aβ42, amyloid ratio, p-tau181, and p-tau181/Aβ42 ratio correlated significantly between plasma and CSF. For these markers, the levels were significantly different in the A + / − , AD + / − , and ATN groups. Amyloid ratio predicts amyloid and AD pathology in CSF with an AUC of 0.89. Conclusions: Plasma biomarkers of AD using the automated Lumipulse platform show good diagnostic performance in detecting Alzheimer’s pathology in cognitively unimpaired subjects.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s13195-023-01319-1

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Some previous studies indicate a poor correlation between plasma and CSF biomarkers, and some indicate a strong correlation.

    “Some of these studies indicate a poor correlation between plasma and CSF biomarkers, 39 and some indicate a strong correlation, 41”

    From A genetic and proteomic comparison of key AD biomarkers across tissues (2024) · cites this paper as [41]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 32

  1. [4]Klunk WE Engler H Nordberg A Imaging brain amyloid in Alzheimer’s disease with Pittsburgh Compound-B Ann Neurol 2004 55 3 306 319 10.1002/ana.20009 14991808 · DOI · Paper page
  2. [5]Brickman AM Manly JJ Honig LS Plasma p-tau181, p-tau217, and other blood-based Alzheimer’s disease biomarkers in a multi-ethnic, community study Alzheimers Dement 2021 17 8 1353 1364 10.1002/alz.12301 33580742 PMC8451860 · DOI · Paper page
  3. [6]Musso G Cosma C Zaninotto M Gabelli C Basso D Plebani M Pre-analytical variability of the Lumipulse immunoassay for plasma biomarkers of Alzheimer’s disease Clin Chem Lab Med 2023 61 3 e53 e56 10.1515/cclm-2022-0770 36423341 · DOI
  4. [7]Fourier A Portelius E Zetterberg H Blennow K Quadrio I Perret-Liaudet A Pre-analytical and analytical factors influencing Alzheimer’s disease cerebrospinal fluid biomarker variability Clin Chim Acta 2015 449 9 15 10.1016/j.cca.2015.05.024 26141614 · DOI
  5. [8]Ashton NJ Pascoal TA Karikari TK Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology Acta Neuropathol 2021 141 5 709 724 10.1007/s00401-021-02275-6 33585983 PMC8043944 · DOI · Paper page
  6. [9]Palmqvist S Janelidze S Quiroz YT Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders JAMA 2020 324 8 772 781 10.1001/jama.2020.12134 32722745 PMC7388060 · DOI · Paper page
  7. [10]Karikari TK Pascoal TA Ashton NJ Blood phosphorylated tau 181 as a biomarker for Alzheimer’s disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts Lancet Neurol 2020 19 5 422 433 10.1016/S1474-4422(20)30071-5 32333900 · DOI · Paper page
  8. [11]Brand AL Lawler PE Bollinger JG The performance of plasma amyloid beta measurements in identifying amyloid plaques in Alzheimer’s disease: a literature review Alzheimers Res Ther 2022 14 195 10.1186/s13195-022-01117-1 36575454 PMC9793600 · DOI · Paper page
  9. [15]Keshavan A Wellington H Chen Z Concordance of CSF measures of Alzheimer’s pathology with amyloid PET status in a preclinical cohort: a comparison of Lumipulse and established immunoassays Alzheimers Dement (Amst) 2021 13 1 e12131 10.1002/dad2.12131 33598527 PMC7867115 · DOI
  10. [16]Wilson EN Young CB Ramos Benitez J Performance of a fully-automated Lumipulse plasma phospho-tau181 assay for Alzheimer’s disease Alzheimers Res Ther 2022 14 1 172 10.1186/s13195-022-01116-2 36371232 PMC9652927 · DOI
  11. [17]López-García S Lage C Pozueta A Sleep time estimated by an actigraphy watch correlates with CSF tau in cognitively unimpaired elders: the modulatory role of APOE Front Aging Neurosci 2021 13 663446 10.3389/fnagi.2021.663446 34408639 PMC8366270 · DOI
  12. [18]Morris JC The Clinical Dementia Rating (CDR): current version and scoring rules Neurology 1993 43 11 2412 2414 10.1212/wnl.43.11.2412-a 8232972 · DOI · Paper page
  13. [19]Folstein MF Folstein SE McHugh PR “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician J Psychiatr Res 1975 12 3 189 198 10.1016/0022-3956(75)90026-6 1202204 · DOI · Paper page
  14. [20]Mattsson N Andreasson U Persson S The Alzheimer’s Association external quality control program for cerebrospinal fluid biomarkers Alzheimers Dement 2011 7 4 386 395.e6 10.1016/j.jalz.2011.05.2243 21784349 PMC3710290 · DOI
  15. [21]Teunissen CE Tumani H Engelborghs S Mollenhauer B Biobanking of CSF: international standardization to optimize biomarker development Clin Biochem 2014 47 4–5 288 292 10.1016/j.clinbiochem.2013.12.024 24389077 · DOI · Paper page
  16. [22]Verberk IMW Misdorp EO Koelewijn J Characterization of pre-analytical sample handling effects on a panel of Alzheimer’s disease-related blood-based biomarkers: results from the Standardization of Alzheimer’s Blood Biomarkers (SABB) working group Alzheimers Dement 2022 18 8 1484 1497 10.1002/alz.12510 34845818 PMC9148379 · DOI
  17. [23]Leitão MJ Silva-Spínola A Santana I Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer’s disease Alzheimers Res Ther 2019 11 1 91 10.1186/s13195-019-0550-8 31759396 PMC6875031 · DOI
  18. [25]Jack CR Bennett DA Blennow K A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers Neurology 2016 87 5 539 547 10.1212/WNL.0000000000002923 27371494 PMC4970664 · DOI · Paper page
  19. [26]CLSI Evaluation of detection capability for clinical laboratory measurement procedures; approved guideline—second edition, CLSI document EP17-A2 2012 Wayne (PA) CLSI
  20. [27]Clark CM Xie S Chittams J Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 2003 60 12 1696 1702 10.1001/archneur.60.12.1696 14676043 · DOI · Paper page
  21. [28]Albert MS DeKosky ST Dickson D The diagnosis of mild cognitive impairment due to Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease Alzheimers Dement 2011 7 3 270 279 10.1016/j.jalz.2011.03.008 21514249 PMC3312027 · DOI · Paper page
  22. [30]Sperling RA Aisen PS Beckett LA Toward defining the preclinical stages of Alzheimer’s disease: recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease Alzheimers Dement 2011 7 3 280 292 10.1016/j.jalz.2011.03.003 21514248 PMC3220946 · DOI · Paper page
  23. [31]Mattsson-Carlgren N Grinberg LT Boxer A Cerebrospinal fluid biomarkers in autopsy-confirmed Alzheimer disease and frontotemporal lobar degeneration Neurology 2022 98 11 e1137 e1150 10.1212/WNL.0000000000200040 35173015 PMC8935438 · DOI
  24. [32]Jansen WJ Janssen O Tijms BM Prevalence estimates of amyloid abnormality across the Alzheimer disease clinical spectrum [published correction appears in JAMA Neurol. 2022 Mar 1;79(3):313] JAMA Neurol 2022 79 3 228 243 10.1001/jamaneurol.2021.5216 35099509 PMC12138908 · DOI · Paper page
  25. [33]Thijssen EH La Joie R Wolf A Diagnostic value of plasma phosphorylated tau181 in Alzheimer’s disease and frontotemporal lobar degeneration Nat Med 2020 26 3 387 397 10.1038/s41591-020-0762-2 32123386 PMC7101073 · DOI · Paper page
  26. [34]Mielke MM Hagen CE Xu J Plasma phospho-tau181 increases with Alzheimer’s disease clinical severity and is associated with tau- and amyloid-positron emission tomography Alzheimers Dement 2018 14 8 989 997 10.1016/j.jalz.2018.02.013 29626426 PMC6097897 · DOI · Paper page
  27. [35]Guo Y Shen XN Wang HF The dynamics of plasma biomarkers across the Alzheimer’s continuum Alzheimers Res Ther 2023 15 31 10.1186/s13195-023-01174-0 36750875 PMC9906840 · DOI
  28. [36]Schindler SE Bollinger JG Ovod V High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis Neurology 2019 93 17 e1647 e1659 10.1212/WNL.0000000000008081 31371569 PMC6946467 · DOI · Paper page
  29. [37]Benedet AL Brum WS Hansson O The accuracy and robustness of plasma biomarker models for amyloid PET positivity Alzheimers Res Ther 2022 14 1 26 10.1186/s13195-021-00942-0 35130933 PMC8819863 · DOI
  30. [38]Ashton NJ Puig-Pijoan A Milà-Alomà M Plasma and CSF biomarkers in a memory clinic: head-to-head comparison of phosphorylated tau immunoassays Alzheimers Dement 2023 19 5 1913 1924 10.1002/alz.12841 36370462 PMC10762642 · DOI · Paper page
  31. [39]Rabe C Bittner T Jethwa A Clinical performance and robustness evaluation of plasma amyloid-β42/40 prescreening Alzheimers Dement 2023 19 4 1393 1402 10.1002/alz.12801 36150024 · DOI
  32. [40]Hansson O Blennow K Zetterberg H Dage J Blood biomarkers for Alzheimer’s disease in clinical practice and trials Nat Aging 2023 3 5 506 519 10.1038/s43587-023-00403-3 37202517 PMC10979350 · DOI · Paper page

Cited by

Sorted by citations

Authors
Martínez-Dubarbie, F., Guerra-Ruiz, A., López-García, S., Lage, C., Fernández-Matarrubia, M., Infante, J., Pozueta-Cantudo, A., García-Martínez, M., Corrales-Pardo, A., Bravo, M., López-Hoyos, M., Irure-Ventura, J., Sánchez-Juan, P., García-Unzueta, M. T., & Rodríguez-Rodríguez, E.
Affiliations
  • Marqués de Valdecilla University Hospital (ES)
  • University of California, San Francisco (US)
  • Universidad de Cantabria (ES)
ORCID
Venue
Alzheimer's Research & Therapy
Publisher
Springer Science and Business Media LLC
Published
2023-10-02
Volume
15
Issue
1
Pages
163-163
ISSN
1758-9193 (ISSN-L)
DOI
10.1186/s13195-023-01319-1
PMC
PMC10544460
OpenAlex
W4387260502
Cited by
47
References
9
Citations by year
2026: 6 · 2025: 19 · 2024: 22
FWCI
9.06
Type
journal article
Language
en
Open access
Licence
Locations
  • Alzheimer s Research & Therapy (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • UCrea (University of Cantabria) (submittedVersion, cc-by)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Physiology › Clinical Laboratory Practices and Quality Control
Keywords
Alzheimer's disease, plasma biomarkers, Aβ40, amyloid-beta 42, phosphorylated tau 181, cerebrospinal fluid biomarkers, amyloid PET, APOE ε4 carriers, amyloid status, biomarker correlation, diagnostic accuracy
MeSH terms
Alzheimer Disease, Amyloid, Humans, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, tau Proteins

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review